We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Chemed (CHE) Q3 Earnings and Revenues Surpass, Margins Rise
Read MoreHide Full Article
Chemed Corporation (CHE - Free Report) reported adjusted earnings per share (EPS) of $5.32 in the third quarter of 2023, up 24.9% year over year. The figure also surpassed the Zacks Consensus Estimate by 8.1%.
The company’s GAAP EPS was $4.93, up 30.4% from last year’s reported figure.
Revenues in Detail
Revenues in the reported quarter improved 7.2% year over year to $564.5 million. The metric beat the Zacks Consensus Estimate by 0.8%.
Chemed Corporation Price, Consensus and EPS Surprise
Chemed operates through two wholly owned subsidiaries — VITAS (a major provider of end-of-life care) and Roto-Rooter (a leading commercial and residential plumbing plus drain cleaning service provider).
VITAS
In the third quarter, net revenues totaled $333.7 million, up 12.5% year over year. This figure compares with our model’s segmental projection of $331.1 million for the third quarter.
The rise in revenues was primarily due to a 9.4% increase in days of care and an increase in the geographically weighted average Medicare reimbursement rate of nearly 2.7%.
Roto-Rooter
The segment reported sales of $230.8 million in the third quarter, up 0.4% year over year. This figure compares with our model’s segmental projection of $227.4 million for the third quarter.
Total Roto-Rooter branch commercial revenues improved 1.5% from the last year, on a 1.8% rise in commercial plumbing, 11.9% growth in excavation revenues and a 2.0% hike in commercial water restoration revenues. This was offset by a 4.2% decrease in drain cleaning revenues.
Total Roto-Rooter branch residential revenues registered an increase of 0.3% over the prior-year period. This consisted of a 0.3% increase in plumbing, 3.2% growth in excavation and a 4.3% increase in water restoration, offset by a 6.7% decrease in drain cleaning.
Margins in Detail
The gross profit increased 12.6% year over year to $202.2 million in the third quarter of 2023. The gross margin expanded 171 basis points (bps) year over year to 35.8% despite an increase in the cost of products and services by 4.5% in the third quarter of 2023.
The adjusted operating profit increased 7.4% from the year-ago period to $102.6 million. The adjusted operating margin expanded 2 bps to 18.2% despite an increase of 18.6% in adjusted operating expenses.
Liquidity & Capital Structure
Chemed exited the third quarter of 2023 with cash and cash equivalents of $173.2 million, which marked a significant increase from $7.8 million at the end of the prior year’s comparable period. Meanwhile, the company did not have any long-term debt at the quarter end compared with $95.9 million at the end of the third quarter of 2022.
The cumulative net cash provided by operating activities at the end of the third quarter of 2023 was $221.7 million compared with $209.7 million in the year-ago period.
During the quarter, the company repurchased 28,457 shares of Chemed stock for $14.3 million, which equates to a cost per share of $504.07. As of Sep 30, 2023, there was approximately $60 million of remaining share repurchase authorization under its plan.
Chemed has a consistent dividend-paying history, with the five-year annualized dividend growth being 6.04%.
2023 Guidance
Chemed provided updated 2023 guidance during the third-quarter earnings call.
The company anticipates 2023 revenues from VITAS, prior to Medicare Cap, to increase in the range of 9.3%-9.5% from the prior year (previously projected at 8.5%-9.5%).
Roto-Rooter is expected to achieve 2023 revenue growth in the range of 1.6-2% (previously 1%-2%).
For 2023, the Zacks Consensus Estimate for total revenues is pegged at $2.25 billion, suggesting 5.4% growth from the 2022 reported figure.
For the full-year 2023, the adjusted EPS is estimated in the range of $19.82-$20.02 (previously $19.90-$20.10). The Zacks Consensus Estimate for the metric is pegged at $19.96, suggesting 1.1% growth over the 2022 adjusted figure.
Our Take
Chemed ended the third quarter of 2023 with better-than-expected earnings and revenues. The performance reflects continued improvement in VITAS' Healthcare segment’s operational metrics, a direct result of the company’s retention and hiring program launched on Jul 1 last year. The Roto-Rooter segment remains well-positioned in spite of economic headwinds on consumer spending. Further, expansion in both margins raises our optimism.
However, within Roto-Rooter, revenues from commercial and residential drain cleaning services posted a decline during the quarter.
Zacks Rank and Key Picks
Chemed currently carries a Zacks Rank #4 (Sell).
Some better-ranked stocks from the broader medical space are Inari Medical , Insulet (PODD - Free Report) and Cencora, Inc. (COR - Free Report) .
Inari Medical, carrying a Zacks Rank #2 (Buy), reported a second-quarter 2023 adjusted EPS of 4 cents, beating the Zacks Consensus Estimate by a staggering 128.6%. Revenues of $119 million outpaced the consensus estimate by 2.3%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Inari Medical has an estimated earnings growth rate of 725% for the next year. Inari Medical’s earnings surpassed estimates in all the trailing four quarters, the average being 66.8%.
Insulet, carrying a Zacks Rank #2, reported a second-quarter 2023 adjusted EPS of 38 cents, which beat the Zacks Consensus Estimate by 58.3%. Revenues of $396.5 million outpaced the consensus estimate by 3.3%.
Insulet has an estimated long-term earnings growth rate of 41.5% compared with the industry’s 14.4% growth. PODD’s earnings surpassed estimates in all the trailing four quarters, the average being 126.9%.
Cencora reported third-quarter fiscal 2023 adjusted earnings of $2.92, which beat the Zacks Consensus Estimate by 3.2%. Revenues of $66.9 billion surpassed the Zacks Consensus Estimate by 5.6%. It currently has a Zacks Rank #2.
Cencora has an earnings yield of 6.8% compared with the industry’s -1.1%. COR’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 3.5%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Chemed (CHE) Q3 Earnings and Revenues Surpass, Margins Rise
Chemed Corporation (CHE - Free Report) reported adjusted earnings per share (EPS) of $5.32 in the third quarter of 2023, up 24.9% year over year. The figure also surpassed the Zacks Consensus Estimate by 8.1%.
The company’s GAAP EPS was $4.93, up 30.4% from last year’s reported figure.
Revenues in Detail
Revenues in the reported quarter improved 7.2% year over year to $564.5 million. The metric beat the Zacks Consensus Estimate by 0.8%.
Chemed Corporation Price, Consensus and EPS Surprise
Chemed Corporation price-consensus-eps-surprise-chart | Chemed Corporation Quote
Segmental Details
Chemed operates through two wholly owned subsidiaries — VITAS (a major provider of end-of-life care) and Roto-Rooter (a leading commercial and residential plumbing plus drain cleaning service provider).
VITAS
In the third quarter, net revenues totaled $333.7 million, up 12.5% year over year. This figure compares with our model’s segmental projection of $331.1 million for the third quarter.
The rise in revenues was primarily due to a 9.4% increase in days of care and an increase in the geographically weighted average Medicare reimbursement rate of nearly 2.7%.
Roto-Rooter
The segment reported sales of $230.8 million in the third quarter, up 0.4% year over year. This figure compares with our model’s segmental projection of $227.4 million for the third quarter.
Total Roto-Rooter branch commercial revenues improved 1.5% from the last year, on a 1.8% rise in commercial plumbing, 11.9% growth in excavation revenues and a 2.0% hike in commercial water restoration revenues. This was offset by a 4.2% decrease in drain cleaning revenues.
Total Roto-Rooter branch residential revenues registered an increase of 0.3% over the prior-year period. This consisted of a 0.3% increase in plumbing, 3.2% growth in excavation and a 4.3% increase in water restoration, offset by a 6.7% decrease in drain cleaning.
Margins in Detail
The gross profit increased 12.6% year over year to $202.2 million in the third quarter of 2023. The gross margin expanded 171 basis points (bps) year over year to 35.8% despite an increase in the cost of products and services by 4.5% in the third quarter of 2023.
The adjusted operating profit increased 7.4% from the year-ago period to $102.6 million. The adjusted operating margin expanded 2 bps to 18.2% despite an increase of 18.6% in adjusted operating expenses.
Liquidity & Capital Structure
Chemed exited the third quarter of 2023 with cash and cash equivalents of $173.2 million, which marked a significant increase from $7.8 million at the end of the prior year’s comparable period. Meanwhile, the company did not have any long-term debt at the quarter end compared with $95.9 million at the end of the third quarter of 2022.
The cumulative net cash provided by operating activities at the end of the third quarter of 2023 was $221.7 million compared with $209.7 million in the year-ago period.
During the quarter, the company repurchased 28,457 shares of Chemed stock for $14.3 million, which equates to a cost per share of $504.07. As of Sep 30, 2023, there was approximately $60 million of remaining share repurchase authorization under its plan.
Chemed has a consistent dividend-paying history, with the five-year annualized dividend growth being 6.04%.
2023 Guidance
Chemed provided updated 2023 guidance during the third-quarter earnings call.
The company anticipates 2023 revenues from VITAS, prior to Medicare Cap, to increase in the range of 9.3%-9.5% from the prior year (previously projected at 8.5%-9.5%).
Roto-Rooter is expected to achieve 2023 revenue growth in the range of 1.6-2% (previously 1%-2%).
For 2023, the Zacks Consensus Estimate for total revenues is pegged at $2.25 billion, suggesting 5.4% growth from the 2022 reported figure.
For the full-year 2023, the adjusted EPS is estimated in the range of $19.82-$20.02 (previously $19.90-$20.10). The Zacks Consensus Estimate for the metric is pegged at $19.96, suggesting 1.1% growth over the 2022 adjusted figure.
Our Take
Chemed ended the third quarter of 2023 with better-than-expected earnings and revenues. The performance reflects continued improvement in VITAS' Healthcare segment’s operational metrics, a direct result of the company’s retention and hiring program launched on Jul 1 last year. The Roto-Rooter segment remains well-positioned in spite of economic headwinds on consumer spending. Further, expansion in both margins raises our optimism.
However, within Roto-Rooter, revenues from commercial and residential drain cleaning services posted a decline during the quarter.
Zacks Rank and Key Picks
Chemed currently carries a Zacks Rank #4 (Sell).
Some better-ranked stocks from the broader medical space are Inari Medical , Insulet (PODD - Free Report) and Cencora, Inc. (COR - Free Report) .
Inari Medical, carrying a Zacks Rank #2 (Buy), reported a second-quarter 2023 adjusted EPS of 4 cents, beating the Zacks Consensus Estimate by a staggering 128.6%. Revenues of $119 million outpaced the consensus estimate by 2.3%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Inari Medical has an estimated earnings growth rate of 725% for the next year. Inari Medical’s earnings surpassed estimates in all the trailing four quarters, the average being 66.8%.
Insulet, carrying a Zacks Rank #2, reported a second-quarter 2023 adjusted EPS of 38 cents, which beat the Zacks Consensus Estimate by 58.3%. Revenues of $396.5 million outpaced the consensus estimate by 3.3%.
Insulet has an estimated long-term earnings growth rate of 41.5% compared with the industry’s 14.4% growth. PODD’s earnings surpassed estimates in all the trailing four quarters, the average being 126.9%.
Cencora reported third-quarter fiscal 2023 adjusted earnings of $2.92, which beat the Zacks Consensus Estimate by 3.2%. Revenues of $66.9 billion surpassed the Zacks Consensus Estimate by 5.6%. It currently has a Zacks Rank #2.
Cencora has an earnings yield of 6.8% compared with the industry’s -1.1%. COR’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 3.5%.